BACKGROUND: Current National Cholesterol Education Program guidelines recommend that non-high-density lipoprotein cholesterol (non-HDL-C) be considered a secondary target of therapy among individuals with triglycerides >2.26 mmol/L. It is not known whether non-HDL-C relates to prognosis among patients with coronary heart disease. METHODS AND RESULTS:Lipid levels were available at baseline among 1514 patients (73% men; mean age, 61 years) enrolled in the Bypass Angioplasty Revascularization Investigation (BARI); all had multivessel coronary artery disease. Patients were followed for 5 years. Outcomes of death, nonfatal myocardial infarction, and death or myocardial infarction were modeled using univariate and multivariate time-dependent proportional hazards methods; angina pectoris at 5 years was modeled using univariate and multivariate logistic regression. Non-HDL-C was a strong and independent predictor of nonfatal myocardial infarction (multivariate relative risk, 1.049 [95% confidence intervals, 1.006 to 1.093] for every 0.26 mmol/L increase) and angina pectoris (multivariate odds ratio, 1.049 [95% confidence intervals, 1.004 to 1.096] for every 0.26 mmol/L increase), but it did not relate to mortality. HDL-C and LDL-C did not predict events during follow-up. CONCLUSIONS: Among patients with lipid values in BARI, non-HDL-C is a strong and independent predictor of nonfatal myocardial infarction and angina pectoris at 5 years, even after consideration of powerful clinical variables. Our data suggest that non-HDL-C is an appropriate treatment target among patients with coronary heart disease.
RCT Entities:
BACKGROUND: Current National Cholesterol Education Program guidelines recommend that non-high-density lipoprotein cholesterol (non-HDL-C) be considered a secondary target of therapy among individuals with triglycerides >2.26 mmol/L. It is not known whether non-HDL-C relates to prognosis among patients with coronary heart disease. METHODS AND RESULTS:Lipid levels were available at baseline among 1514 patients (73% men; mean age, 61 years) enrolled in the Bypass Angioplasty Revascularization Investigation (BARI); all had multivessel coronary artery disease. Patients were followed for 5 years. Outcomes of death, nonfatal myocardial infarction, and death or myocardial infarction were modeled using univariate and multivariate time-dependent proportional hazards methods; angina pectoris at 5 years was modeled using univariate and multivariate logistic regression. Non-HDL-C was a strong and independent predictor of nonfatal myocardial infarction (multivariate relative risk, 1.049 [95% confidence intervals, 1.006 to 1.093] for every 0.26 mmol/L increase) and angina pectoris (multivariate odds ratio, 1.049 [95% confidence intervals, 1.004 to 1.096] for every 0.26 mmol/L increase), but it did not relate to mortality. HDL-C and LDL-C did not predict events during follow-up. CONCLUSIONS: Among patients with lipid values in BARI, non-HDL-C is a strong and independent predictor of nonfatal myocardial infarction and angina pectoris at 5 years, even after consideration of powerful clinical variables. Our data suggest that non-HDL-C is an appropriate treatment target among patients with coronary heart disease.
Authors: K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati Journal: Indian Heart J Date: 2014-12-24
Authors: Andrea Kelly; Sheela N Magge; Rachel Walega; Claire Cochrane; Mary E Pipan; Babette S Zemel; Meryl S Cohen; Samuel S Gidding; Ray Townsend Journal: J Pediatr Date: 2019-06-11 Impact factor: 4.406
Authors: T Scott Stroup; Joseph P McEvoy; Kimberly D Ring; Robert H Hamer; Lisa M LaVange; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Abraham M Nussbaum; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2011-07-18 Impact factor: 18.112
Authors: Paramjit K Sandhu; Salma M A Musaad; Alan T Remaley; Stephanie S Buehler; Sonya Strider; James H Derzon; Hubert W Vesper; Anne Ranne; Colleen S Shaw; Robert H Christenson Journal: J Appl Lab Med Date: 2016-08-01
Authors: Hendrick E van Deventer; W Greg Miller; Gary L Myers; Ikunosuke Sakurabayashi; Lorin M Bachmann; Samuel P Caudill; Andrzej Dziekonski; Selvin Edwards; Mary M Kimberly; William J Korzun; Elizabeth T Leary; Katsuyuki Nakajima; Masakazu Nakamura; Robert D Shamburek; George W Vetrovec; G Russell Warnick; Alan T Remaley Journal: Clin Chem Date: 2011-01-12 Impact factor: 8.327
Authors: Amy S Shah; Elaine M Urbina; Philip R Khoury; Thomas R Kimball; Lawrence M Dolan Journal: J Clin Lipidol Date: 2013-05-18 Impact factor: 4.766
Authors: G Bos; J M Dekker; G Nijpels; F de Vegt; M Diamant; C D A Stehouwer; L M Bouter; R J Heine Journal: Diabetologia Date: 2003-06-18 Impact factor: 10.122